Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Unipath Diagnostics

This article was originally published in The Tan Sheet

Executive Summary

Unipath Diagnostics: Patricia Nasshorn to president of the Unilever reproductive diagnostics division. She formerly was VP-marketing at J&J's Direct Access Diagnostics, which marketed the discontinued Confide home HIV test. Nasshorn succeeds Alastair Paton, Unipath's general manager, who will oversee the company's business development outside the U.S. and Europe. Unipath is conducting clinical trials for an electronic monitor system for birth control ("The Tan Sheet" June 9, p. 4). Work also is under way on a fertility monitor that employs the same technology. Unipath reacquired the Clearblue Easy home pregnancy test and Clearplan Easy ovulation predictor from Whitehall-Robins upon its formation in January and launched the Clearblue Easy One Minute pregnancy test in May. The firm plans to move its headquarters from New York City to Princeton, N.J. in 1998...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel